Sonia Aladren and Massimo Milani are ISDIN employees. The ACTUO study was supported by an unrestricted grant of ISDIN SA.
RDL, GMA, MPL, AVC participated in the study design, coordination and patients enrollment. MM and SA participated in the design of study protocol and data analysis. All authors read and approved the final manuscript.
In acne, several studies report a poor adherence to treatments. We evaluate, in a real-life setting conditions, the impact of compliance to physician’s instructions, recommendations and adherence to the treatments on clinical outcome in patients with mild to moderate acne in an observational, non-interventional prospective study carried out in 72 Dermatologic Services in Spain (ACTUO Trial).
Six-hundred-forty-three subjects were enrolled and 566 patients (88 %) completed the 3 study visits. Study aimed to evaluate the impact of adherence (assessed with ECOB scale) on clinical outcome, as well as how the use of specific adjuvant treatments (facial cleansing, emollient, moisturizing and lenitive specific topical products) influences treatment’s adherence and acne severity (0–5 points score). Recommendation of specific adjuvant skin barrier repair products was made in 85.2 %.
Overall, clinical improvement was observed throughout follow-up visits with an increased proportion of patients who reported reductions of ≥50 % on the total number of lesions (2 months: 25.2 %; 3 months: 57.6 %) and reductions of severity scores (2.5, 2.0 and 1.3 at 1, 2 and 3 months after treatment, respectively). Adherence to treatment was associated with a significant reduction on severity grading, a lower number of lesions and a higher proportion of patients with ≥50 % improvement.
Good adherence to medication plus adherence to adjuvants was significantly associated with a higher clinical improvement unlike those that despite adherence with medication had a low adherence to adjuvants. A good adherence to adjuvant treatment was associated with improved adherence and better treatment outcomes in mild to moderate acne patients. (ISRCTN Registry: ISRCTN14257026).
Goulden V. Guidelines for the management of acne vulgaris in adolescents. Pediatr Drugs. 2003;5:301–13. CrossRef
Russell JJ. Topical therapy for acne. Am Fam Physician. 2000;61:357–65. PubMed
Del Rosso JQ. Clinical relevance of skin barrier changes associated with the use of oral isotretinoin: the importance of barrier repair therapy in patient management. J Drugs Dermatol. 2013;12:626–31. PubMed
US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry; AcneVulgaris: Developing Drugs for Treatment. 2005.
De Tiedra AG, Mercadal J, Badía X, Mascaró JM, Herdman M, Lozano R. Adaptación transcultural al español del cuestionario Dermatology Life Quality Index (DLQI): El índice de calidad de vida en dermatología. Actas Dermatosifilogr. 1998;89:692–700.
- Adherence to drug treatments and adjuvant barrier repair therapies are key factors for clinical improvement in mild to moderate acne: the ACTUO observational prospective multicenter cohort trial in 643 patients
Raúl de Lucas
on behalf of ACTUO Investigators study group
- BioMed Central
Neu im Fachgebiet Dermatologie
Meistgelesene Bücher aus dem Fachgebiet
Mail Icon II